Table 3

Median questioning scores and IQR over time by scenario

ScenarioVisits 1–3 (%)Visits 4–6 (%)Visits 7–9 (%)Overall (%)Improvement over time*
Adult cough/cold (n=52)37 (IQR=25–67)58 (IQR=40–83)64 (IQR=50–83)58 (IQR=33–83)Yes (P=0.003)
Adult pain (n=52)46 (IQR=21–86)57 (IQR=43–79)64 (IQR=50–100)57 (IQR=39–86)Yes (P=0.008)
Allergic rhinitis (n=50)25 (IQR=0–72)31 (IQR=0–50)33 (IQR=0–50)28 (IQR=0–50)No (P=0.929)
Asthma (n=54)30 (IQR=14–64)42 (IQR=31–72)62 (IQR=36–86)44 (IQR=25–72)Yes (P=0.004)
Diarrhoea (n=51)44 (IQR=19–81)44 (IQR=28–73)44 (IQR=25–66)44 (IQR=25–70)No (P=0.707)
Dyspepsia (n=53)50 (IQR=25–81)75 (IQR=21–81)75 (IQR=13–89)63 (IQR=22–81)No (P=0.198)
Insomnia (n=53)44 (IQR=25–63)69 (IQR=50–81)56 (IQR=25–78)56 (IQR=33–78)No (P=0.274)
Paediatric cough/cold (n=54)22 (IQR=14–50)28 (IQR=25–50)38 (IQR=25–50)30 (IQR=19–50)No (P=0.227)
Paediatric fever (n=51)11 (IQR=11–22)39 (IQR=17–56)44 (IQR=25–72)22 (IQR=11–56)Yes (P=0.002)
Smoking cessation (n=51)44 (IQR=22–83)53 (IQR=25–69)58 (IQR=28–94)56 (IQR=22–78)No (P=0.290)
All (n=521)38 (IQR=14–64)50 (IQR=25–72)50 (IQR=26–76)44 (IQR=22–75)Yes (P<0.001)
  • *Significance determined by Spearman’s rank order correlations, P<0.05.